Learn what’s in store for AI in clinical research with Advarra’s Chief Technology Officer.
This staff-written feature article discusses the predictions for 2025 from industry leaders, including Advarra’s Jeff…
Experts discuss what to expect in drug development in 2025, including ways to break the…
In this article, Biopharma Trend does a deep-dive into Advarra’s 2024 Site/Sponsor/CRO Collaboration survey results,…
Trial Site News offers a new spin on Advarra’s 2024 Site-Sponsor/CRO Collaboration Survey report —…
Learn the surprising results of Advarra’s 2024 Site-Sponsor/CRO Collaboration survey including the barriers to better…
See this staff-written news brief highlighting AMR’s selection of Longboat.
This insightful article on study startup challenges includes insights from sites, sponsors, and CROs.
In this important article on women’s health and difficulties of accessing IVF, Elisa Cascade provides…
Barbara Schneider provides valuable insights on the important role of data monitoring committees — and…
James Riddle outlines the impact of the anticipated sIRB mandate, and argues how this is…
Advarra CEO Gadi Saarony explores diversity and equity in clinical research, emphasizing trust as the…
Advarra CEO Gadi Saarony discusses the importance of diversity, inclusion, and trust in clinical research…
This article features an in-depth review of the future of decentralized clinical trials from the…
The future of clinical research is a connected user experience with automated workflows, streamlined document…
The FDA's new draft guidance mandates Diversity Action Plans for phase 3 clinical trials to…
Pamela Tenaerts, MD, MBA, chief scientific officer, Medable; Luke Gelinas, PhD, senior chair director, Advarra;…
The U.S. clinical trial landscape is growing, driven by new technologies, but faces challenges like…
On May 16, 2024, Applied Clinical Trials held a roundtable event focused on the current…
Improving trial feasibility through better collaboration and automation can significantly reduce the administrative burden on…
Christine Senn highlights the importance of thorough feasibility processes in rare disease trials. The need…
In 2023, the FDA approved 55 new drugs and five gene therapies for rare diseases.…
Once the FDA’s sIRB mandate is in effect, it will affect the remainder of non-federally…
As the United States continues to grapple with politics and science meeting, the global healthcare…
The National Institutes of Health (NIH) has chosen Advarra as its exclusive single institutional review…
Asia-Pacific's clinical trials market success is driven by innovative strategies, robust infrastructure, and regulatory support.
Advarra and WCG, leaders in the IRB industry, collaborate with SASI to endorse and support…
Gene therapies pose several unique challenges for clinical research, including ethical and safety considerations, regulatory…
Single sign-on technology is now easing the burden on study sites, improving efficiency and security…
Read more: https://www.outsourcing-pharma.com/Article/2024/03/01/James-Riddlle-of-Advarra-shares-insights-on-clinical-trial-engagement
To register for upcoming webinars and see where we’ll be next, go to the Events page
Want to see the latest news and updates about Advarra? You can find them in the Newsroom